Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 23;8(1):6.
doi: 10.1186/s41181-023-00192-5.

Highlight selection of radiochemistry and radiopharmacy developments by editorial board

Oliver C Kiss  1 , Peter J H Scott  2 , Martin Behe  3 , Ivan Penuelas  4 , Jan Passchier  5 , Ana Rey  6 , Marianne Patt  7 , Silvio Aime  8 , Amir Jalilian  9 , Peter Laverman  10 , Zhen Cheng  11 , Alain Faivre Chauvet  12 , Jonathan Engle  13 , Frederik Cleeren  14 , Hua Zhu  15 , Johnny Vercouillie  16 , Michael van Dam  17 , Ming Rong Zhang  18 , Lars Perk  10 , Benjamin Guillet  19 , Francisco Alves  20
Affiliations
Review

Highlight selection of radiochemistry and radiopharmacy developments by editorial board

Oliver C Kiss et al. EJNMMI Radiopharm Chem. .

Abstract

Background: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development.

Main body: This selection of highlights provides commentary on 21 different topics selected by each coauthoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first-in-human application of novel radiopharmaceuticals.

Conclusion: Trends in radiochemistry and radiopharmacy are highlighted. Hot topics cover the entire scope of EJNMMI Radiopharmacy and Chemistry, demonstrating the progress in the research field, and include new PET-labelling methods for 11C and 18F, the importance of choosing the proper chelator for a given radioactive metal ion, implications of total body PET on use of radiopharmaceuticals, legislation issues and radionuclide therapy including the emerging role of 161Tb.

Keywords: Highlight articles; Nuclear medicine; Radiochemistry; Radiopharmaceutical Sciences; Radiopharmacy; Trends in radiopharmaceutical sciences.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Synthetic scheme for synthesis of 11C-amino acids through isotopic exchange catalyzed by benzaldehyde
Fig. 2
Fig. 2
AR42J tumor cell viability (MTT assay) and Kaplan–Meier plot (2 × 10 MBq; 0.2 nmol) for 161Tb- and 177Lu-labeled SSTR agonists (DOTATOC) and antagonists (DOTA-LM3) in AR42J tumor-bearing mice. (adapted from Borgna et al. 2022)
Fig. 3
Fig. 3
Overview of use of new H2BZmacropa chelator, its conjugation to an antibody and biodistribution results. (from Bioconjugate Chem. 2022;33, 6, 1222–1231)
Fig. 4
Fig. 4
A 68Ga-DOTANOC and B 18 F-AlF-OC images (from top to bottom: maximum-intensity projection PET, transversal PET and fused PET/CT images, respectively) of a seventy-year old male patient with an intestinal neuroendocrine tumor with multiple liver metastases and one involved lymph node. 18 F-AlF-OC detected an additional bone lesion (blue arrow) that was confirmed by C follow-up 68Ga-DOTANOC imaging 6 months later. Lookup tables apply to PET images (SUV). (From Pauwels et al. 2022)
Fig. 5
Fig. 5
Schematic overview of preclinical experiments to evaluate 99mTc labelled EGFR imaging agents. (from Kiritsis et al. 2022)
Fig. 6
Fig. 6
Schematic overview of [18F]difluorocarbene precursors obtained through a halogen exchange 18F/Br of (bromofluoromethyl)(4-chlorophenyl)sulfane starting material, followed by an oxidation step. Examples of produced 18F-radioligands are presented
Fig. 7
Fig. 7
Structure of [18F]8
See this image and copyright information in PMC

Similar articles

  • Highlight selection of radiochemistry and radiopharmacy developments by editorial board.
    DaSilva J, Decristoforo C, Mach RH, Bormans G, Carlucci G, Al-Qahtani M, Duatti A, Gee AD, Szymanski W, Rubow S, Hendrikx J, Yang X, Jia H, Zhang J, Caravan P, Yang H, Zeevaart JR, Rodriquez MA, Oliveira RS, Zubillaga M, Sakr T, Spreckelmeyer S. DaSilva J, et al. EJNMMI Radiopharm Chem. 2023 Oct 27;8(1):35. doi: 10.1186/s41181-023-00218-y. EJNMMI Radiopharm Chem. 2023. PMID: 37889361 Free PMC article. Review.
  • Highlight selection of radiochemistry and radiopharmacy developments by editorial board.
    Toyohara J, Vugts D, Kiss OC, Todde S, Li XG, Liu Z, Yang Z, Gillings N, Cazzola E, Szymanski W, Meulen NV, Reilly R, Taddei C, Schirrmacher R, Li Z, Lagebo YJ, Bentaleb N, Souza Albernaz M, Lapi S, Ramogida C, Mukherjee A, Ajenjo J, Deuther-Conrad W, Bourdeau C. Toyohara J, et al. EJNMMI Radiopharm Chem. 2024 May 16;9(1):42. doi: 10.1186/s41181-024-00268-w. EJNMMI Radiopharm Chem. 2024. PMID: 38753262 Free PMC article. Review.
  • Highlight selection of radiochemistry and radiopharmacy developments by editorial board.
    Toyohara J, Al-Qahtani M, Huang YY, Cazzola E, Todde S, Furumoto S, Mikolajczak R, Decristoforo C, Gillings N, Yang M, Reilly R, Duatti A, Denkova A, Schirrmacher R, Carlucci G, Seimbille Y, Liu Z, Ellis B, Cornelissen BT, Kopka K, Bernardes E. Toyohara J, et al. EJNMMI Radiopharm Chem. 2022 Oct 1;7(1):25. doi: 10.1186/s41181-022-00177-w. EJNMMI Radiopharm Chem. 2022. PMID: 36182995 Free PMC article. Review.
  • Highlight selection of radiochemistry and radiopharmacy developments by editorial board.
    Scott PJ, Penuelas I, Rey A, Aime S, Ambikalmajan PMR, Antunes IF, Cleeren F, Liu Z, Ellis B, Kahts M, Ekoume FP, Chaple IF, Bernardes E, Behe M, Huang YY, Mikolajczak R, Furumoto S, Elrefaei A, Kopka K. Scott PJ, et al. EJNMMI Radiopharm Chem. 2024 Sep 16;9(1):67. doi: 10.1186/s41181-024-00296-6. EJNMMI Radiopharm Chem. 2024. PMID: 39283414 Free PMC article. Review.
  • Highlight selection of radiochemistry and radiopharmacy developments by editorial board.
    Spreckelmeyer S, Dasilva J, Decristoforo C, Mach RH, Passchier J, Carlucci G, Qahtani MA, Duatti A, Cornelissen BT, Engle J, Denkova A, Hendrikx JJMA, Seimbille Y, Yang X, Jia H, Zhang MR, Yang M, Perk L, Caravan P, Laverman P, Cheng Z, Hoehr C, Sakr T, Zeevaart JR. Spreckelmeyer S, et al. EJNMMI Radiopharm Chem. 2025 Mar 25;10(1):13. doi: 10.1186/s41181-025-00335-w. EJNMMI Radiopharm Chem. 2025. PMID: 40131608 Free PMC article. Review.
See all similar articles

Cited by

References

    1. Barnes C, Nair M, Aboagye EO, Archibald SJ, Allott L. A practical guide to automating fluorine-18 PET radiochemistry using commercially available cassette-based platforms. React Chem Eng. 2022;7:2265–79. doi: 10.1039/D2RE00219A. - DOI
    1. Bartos LM, Kunte ST, Beumers P, Xiang X, Wind K, Ziegler S, Bartenstein P, Choi H, Lee DS, Haass C, Baumgarten LV, Tahirovic S, Albert NL, Lindner S, Brendel M. Single-cell radiotracer allocation via immunomagnetic sorting to disentangle PET signals at cellular resolution. J Nucl Med. 2022;63:1459–62. doi: 10.2967/jnumed.122.264171. - DOI - PMC - PubMed
    1. Borgna F, Haller S, Rodriguez JMM, Ginj M, Grundler PV, Zeevaart JR, Koster U, Schible R, van der Meulen NP, Muller C. Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroeondocrine neoplasms. Eur J Nucl Med Mol Imaging. 2022;49:1113–26. doi: 10.1007/s00259-021-05564-0. - DOI - PMC - PubMed
    1. Bsharat O, Doyle MGJ, Munch M, Mair BA, Cooze CJC, Derdau V, Bauer A, Kong D, Rotstein BH, Lundgren RJ. Radiosynthesis of α-amino acids by exchanging aldehyde-catalyzed carboxylate with 11CO2. Aldehyde-catalysed carboxylate exchange in α-amino acids with isotopically labelled CO2. Nat Chem. 2022;14:1367–74. doi: 10.1038/s41557-022-01074-0. - DOI - PubMed
    1. CCS Task Force issues new Guideline. Contamination Control Strategy (CCS) A New Guideline from ECA. https://www.eca-foundation.org/news/ccs-task-force-issues-new-guideline..... Accessed 29 Jan 2023.